Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523777 · ClinicalTrials.gov registry record
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by Yale University.
- Recruiting
- Registry status
- 350
- Enrollment target
- 7
- Study locations
NCT06523777 is a study of Prostate Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 350 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06523777, a study of Prostate Cancer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
Conditions Studied
Study Locations (7)
Connecticut
- Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center - Bridgeport
- Griffin Hospital - Derby
- Yale New Haven Health Greenwich Hospital - Greenwich
- Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion): - New Haven
- Saint Raphael's Radiology and Biomedical Imaging, Basement Location. - New Haven
- Yale New Haven Health Lawrence & Memorial Hospital - New London
Rhode Island
- Yale New Haven Health Westerly Hospital - Westerly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06523777
The ClinicalTrials.gov registry entry for NCT06523777 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06523777 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06523777 about?
NCT06523777 is a clinical study titled "PRISM: Patient Experiences With PET Imaging in Prostate Cancer". The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic c...
What is the current status of trial NCT06523777?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2024-07-25. Estimated completion is 2028-07.
What conditions does trial NCT06523777 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT06523777?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06523777 being conducted?
This trial has 7 study locations across Connecticut, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.